/
Working Group Report – Q1 2025

Working Group Report – Q1 2025

            

Working Groups – Q1  2025 Summary 

Welcome to the PHUSE Quarter 1 2025 Working Group Report Summary.

It has been a great start to 2025, with new projects being approved, new deliverables and lots of events! We also had an exciting announcement: the Emerging Trends and Technologies Working Group has changed its name to Emerging Trends and Innovation! 

Why the change? Working Group Lead Mike Hamidi shares what brought about this change of name and scope: 

“The name change from Emerging Trends and Technologies to Emerging Trends and Innovation reflects a broader focus beyond technological enablement. This shift encompasses ongoing developments in areas such as AI/ML, digital health technologies, and healthcare standards and aims to provide deeper insights into these and other evolving topics. This adjustment will preserve the emphasis on emerging trends while enhancing our commitment to delivering valuable industry insights and innovations.” 

We are equally excited to welcome Mark Bynens, the new Working Group Lead. Mark joins Mike Hamidi and Stuart Malcolm. 

Mark brings a wealth of experience as Director and Scientific Computing Operations (SCO) Head within Statistics & Decision Sciences (SDS), Global Development at Johnson & Johnson. Mark leads initiatives in change management, project management, education, high-performance computing and statistical research. 

New Projects This Quarter

Four of the Working Groups have expanded, with seven new projects this quarter: 

Published Deliverables 

We have two more published deliverables this quarter:

Optimizing the Use of Data Standards

SDTM ADaM Implementation FAQ

Safety Analytics

Analyses & Displays for Hepatotoxicity

This white paper provides recommendations for displaying, summarising and analysing measures of hepatotoxicity in tables, figures and listings (TFLs). The suggested TFLs will have implications for what and how liver-related data should be collected. If the data required to populate these TFLs is not collected, then there may be insufficient information to adequately assess the potential for a drug to cause or contribute to the cause of hepatotoxicity. 

Under Review 

Under Review 

Related content